{"protocolSection":{"identificationModule":{"nctId":"NCT00211705","orgStudyIdInfo":{"id":"MEGA"},"organization":{"fullName":"Mitsukoshi Health and Welfare Foundation","class":"INDUSTRY"},"briefTitle":"Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)","officialTitle":"Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)"},"statusModule":{"statusVerifiedDate":"2005-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"1994-02"},"completionDateStruct":{"date":"2004-03"},"studyFirstSubmitDate":"2005-09-13","studyFirstSubmitQcDate":"2005-09-13","studyFirstPostDateStruct":{"date":"2005-09-21","type":"ESTIMATED"},"lastUpdateSubmitDate":"2006-11-30","lastUpdatePostDateStruct":{"date":"2006-12-04","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Mitsukoshi Health and Welfare Foundation","class":"INDUSTRY"},"collaborators":[{"name":"Daiichi Sankyo Co., Ltd.","class":"INDUSTRY"},{"name":"Ministry of Health, Labour and Welfare, Japan","class":"OTHER_GOV"}]},"descriptionModule":{"briefSummary":"To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.","detailedDescription":"MEGA Study is the first prospective, randomized, controlled trial conducted in Japan to evaluate the primary preventive effect of pravastatin against CHD in daily clinical practice. Because the dose of pravastatin used in the MEGA Study was 10-20 mg/day, which is consistent with the approved doses in Japan and lower than the doses used in previous large-scale clinical trials."},"conditionsModule":{"conditions":["Hyperlipidemia"],"keywords":["Hyperlipidemia","coronary heart disease","prevention","stroke","pravastatin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":8000}},"armsInterventionsModule":{"interventions":[{"type":"BEHAVIORAL","name":"Diet"},{"type":"DRUG","name":"Diet+pravastatin"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Coronary Heart Disease(CHD)[fatal/non-fatal MI, sudden/cardiac death, angina, revascularization]"}],"secondaryOutcomes":[{"measure":"Stroke, cerebrovascular infarction(CI), CHD+CI, all cardiovascular events, total mortality"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* TC:220ï½ž270mg/dl\n* Male: 40-70 years old/ female: postmenopausal-70 years old\n* \\<40kg in weight\n\nExclusion Criteria:\n\n* FH\n* History of CHD(angina, MI, post-PTCA/CABG, etc.)\n* History of CVA(stroke, TIA, etc.)\n* Underlying malignant tumor","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Haruo Nakamura, MD","affiliation":"Mitsukoshi Health and Welfare","role":"STUDY_CHAIR"}]},"referencesModule":{"references":[{"pmid":"15329509","type":"BACKGROUND","citation":"Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J. 2004 Sep;68(9):860-7. doi: 10.1253/circj.68.860."},{"pmid":"17011942","type":"RESULT","citation":"Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006 Sep 30;368(9542):1155-63. doi: 10.1016/S0140-6736(06)69472-5."},{"pmid":"25135178","type":"DERIVED","citation":"Nakamura H, Mizuno K; MEGA Study Group. Cardiovascular and cancer events in hyper-high-density lipoprotein cholesterolemic patients: a post hoc analysis of the MEGA study. Lipids Health Dis. 2014 Aug 18;13:133. doi: 10.1186/1476-511X-13-133."},{"pmid":"22573644","type":"DERIVED","citation":"Matsushima T, Nakaya N, Mizuno K, Ohashi Y, Teramoto T, Yokoyama S, Ichikawa S, Ishikura N, Kamiyama K, Nakamura H; MEGA Study Group. The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study. J Cardiovasc Pharmacol Ther. 2012 Jun;17(2):153-8. doi: 10.1177/1074248411421777. Epub 2011 Oct 3."},{"pmid":"24843520","type":"DERIVED","citation":"Tajima N, Kurata H, Ohashi Y, Mizuno K, Nakamura H. Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study assists the view that a fasting plasma glucose level >/=100 mg/dL increases cardiovascular risk. J Diabetes Investig. 2011 Oct 7;2(5):399-405. doi: 10.1111/j.2040-1124.2011.00121.x."},{"pmid":"21815708","type":"DERIVED","citation":"Nakaya N, Mizuno K, Ohashi Y, Teramoto T, Yokoyama S, Hirahara K, Mizutani M, Nakamura H; MEGA Study Group. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging. 2011 Sep 1;28(9):681-92. doi: 10.2165/11595620-000000000-00000."},{"pmid":"21593784","type":"DERIVED","citation":"Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Teramoto T, Yokoyama S, Kakinoki S, Nakamura H; MEGA Study Group. Blood pressure control status and effects of pravastatin on cardiovascular events occurrence in patients with dyslipidaemia. J Hum Hypertens. 2012 Jun;26(6):388-95. doi: 10.1038/jhh.2011.49. Epub 2011 May 19."},{"pmid":"19423108","type":"DERIVED","citation":"Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y; MEGA Study Group. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009 Oct;206(2):512-7. doi: 10.1016/j.atherosclerosis.2009.03.031. Epub 2009 Apr 5."},{"pmid":"19104004","type":"DERIVED","citation":"Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Teramoto T, Uchiyama S, Nakamura H; Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study Group. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension. 2009 Feb;53(2):135-41. doi: 10.1161/HYPERTENSIONAHA.108.120584. Epub 2008 Dec 22."},{"pmid":"18172039","type":"DERIVED","citation":"Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, Uchiyama S, Nakamura H; MEGA Study Group. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation. 2008 Jan 29;117(4):494-502. doi: 10.1161/CIRCULATIONAHA.106.671826. Epub 2008 Jan 2."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000006949","term":"Hyperlipidemias"},{"id":"D000006951","term":"Hyperlipoproteinemias"},{"id":"D000006937","term":"Hypercholesterolemia"}],"ancestors":[{"id":"D000050171","term":"Dyslipidemias"},{"id":"D000052439","term":"Lipid Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M6236","name":"Coronary Artery Disease","relevance":"LOW"},{"id":"M6239","name":"Coronary Disease","relevance":"LOW"},{"id":"M9690","name":"Hyperlipidemias","asFound":"Hyperlipidemia","relevance":"HIGH"},{"id":"M19196","name":"Myocardial Ischemia","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M9678","name":"Hypercholesterolemia","asFound":"Elevated Cholesterol","relevance":"HIGH"},{"id":"M9692","name":"Hyperlipoproteinemias","asFound":"Hyperlipidemia","relevance":"HIGH"},{"id":"M25871","name":"Dyslipidemias","relevance":"LOW"},{"id":"M11329","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M26719","name":"Lipid Metabolism Disorders","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000017035","term":"Pravastatin"}],"ancestors":[{"id":"D000000924","term":"Anticholesteremic Agents"},{"id":"D000000960","term":"Hypolipidemic Agents"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000057847","term":"Lipid Regulating Agents"},{"id":"D000019161","term":"Hydroxymethylglutaryl-CoA Reductase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M19058","name":"Pravastatin","asFound":"Maxillary","relevance":"HIGH"},{"id":"M3933","name":"Anticholesteremic Agents","relevance":"LOW"},{"id":"M3968","name":"Hypolipidemic Agents","relevance":"LOW"},{"id":"M3971","name":"Antimetabolites","relevance":"LOW"},{"id":"M28573","name":"Lipid Regulating Agents","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}